You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1(L1)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HPV-unrelated Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Palbociclib, Cetuximab)

Recruiting
  • HPV-unrelated Head and Neck Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 7, 2022

NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma Breast
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 29, 2022

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Advanced Lung Cancer Trial (6MW3211)

Not yet recruiting
  • Advanced Lung Cancer
  • (no location specified)
Jun 20, 2022

Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays

Not yet recruiting
  • Lung Neoplasm
  • +2 more
  • Tumor samples
  • Bordeaux, France
    CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médic
Aug 28, 2023

Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Chuo-ku, Tokyo, Japan
    National Cancer Center Hospital ( Site 3700)
Jan 31, 2023

Head Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck Trial

Not yet recruiting
  • Head and Neck Cancer
  • +4 more
  • Ozuriftamab Vedotin
  • PD-1 inhibitor
  • (no location specified)
Jul 28, 2022

PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • L-DEP and PD-1 antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 8, 2023

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in

Not yet recruiting
  • Metastatic Triple-Negative Breast Carcinoma
  • 89Zr-atezolizumab PET/CT
  • (no location specified)
Feb 22, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Gastric Adenocarcinoma Trial (cadonilimab combined +paclitaxel (albumin-bound))

Not yet recruiting
  • Gastric Adenocarcinoma
  • cadonilimab combined +paclitaxel (albumin-bound)
  • (no location specified)
Nov 1, 2023

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)

Not yet recruiting
  • Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
  • SG001 injection
  • +5 more
  • (no location specified)
Jan 27, 2023

Refractory Cutaneous Melanoma Trial in Portland (Ipilimumab, Nivolumab, Cabozantinib)

Recruiting
  • Refractory Cutaneous Melanoma
  • Portland, Oregon
    Providence Portland Medical Center
Jun 8, 2022

High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8

Not yet recruiting
  • High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
  • +3 more
  • PD-L1/IDO Peptide Vaccine
  • Pembrolizumab
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Apr 24, 2023

Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,

Recruiting
  • Metastatic Gastric Cancer
  • +2 more
  • New York, New York
    Bureau for Cancer Research
May 10, 2023

Advanced NSCLC Trial (BNT116, Cemiplimab)

Not yet recruiting
  • Advanced Non-Small Cell Lung Cancer
  • (no location specified)
Jan 3, 2023

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

Metastatic Microsatellite-stable Colorectal Cancer Trial (LB-100, Atezolizumab)

Not yet recruiting
  • Metastatic Microsatellite-stable Colorectal Cancer
  • (no location specified)
Sep 1, 2023

NSCLC, Lung Diseases, Lung Tumors Trial in New Haven (Sitravatinib, Pembrolizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +8 more
  • New Haven, Connecticut
    Yale University
Oct 26, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal

Not yet recruiting
  • Nasopharyngeal and Hypopharyngeal Carcinoma
  • immunohistochemical
  • Sohag, Egypt
    Sohag University Hospital
Oct 23, 2022

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

Oncology, NSCLC Stage IV, NSCLC, Stage III Trial in Drammen (UV1, Sagramostim, Anti-PD-1/PD-L1 treatment)

Recruiting
  • Oncology
  • +2 more
  • UV1
  • +2 more
  • Drammen, Viken, Norway
    Vestre Viken Health Trust
Aug 15, 2022